Drug Profile
CX 717
Alternative Names: Ampakine® CX717; CX-717Latest Information Update: 16 Mar 2022
Price :
$50
*
At a glance
- Originator Cortex Pharmaceuticals
- Developer Cortex Pharmaceuticals; National Institute of Drug Abuse; RespireRx Pharmaceuticals
- Class 2 ring heterocyclic compounds; Antidementias; Morpholines; Nootropics; Oxadiazoles; Small molecules
- Mechanism of Action AMPA receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Attention-deficit hyperactivity disorder; Respiratory insufficiency
- Phase I Spinal cord injuries
- No development reported Substance-related disorders
- Discontinued Alzheimer's disease; Sleep disorders
Most Recent Events
- 10 Mar 2022 RespireRxin plans a phase II trial in Spinal-cord-injuries
- 07 Mar 2022 CX 717 is still in phase-I development in Spinal-cord-injuries in Unknown
- 07 Mar 2022 RespireRx Pharmaceuticals submites patent applications for CX 717 for Spinal cord injury and Attention deficit hyperactivity disorder